Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37
Received 8 September 2019
Accepted for publication 7 November 2019
Published 10 December 2019 Volume 2019:14 Pages 9777—9792
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Thomas J. Webster
Somayeh Sadeghi,1,2 Haleh Bakhshandeh,1 Reza Ahangari Cohan,1 Afshin Peirovi,1 Parastoo Ehsani,2 Dariush Norouzian1
1Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran; 2Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
Correspondence: Parastoo Ehsani
Department of Molecular Biology, Pasteur Institute of Iran, #69 Pasteur Avenue, Tehran 13164, Iran
Tel + 98 21 64112219
Fax + 98 21 64112803
Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, #69 Pasteur Avenue, Tehran 13164, Iran
Tel + 98 21 64112137
Fax + 98 21 66465132
Purpose: Staphylococcus aureus is the most common persistent pathogen in humans, so development of new formulations to combat pathogen invasion is quite necessary.
Methods: In the current study, for the first time, the synergistic activity of recombinant lysostaphin and LL-37 peptide was studied against S. aureus. Moreover, different niosomal formulations of the peptide and protein were prepared and analyzed in terms of size, shape, zeta potential, and entrapment efficiency. Also, a long-term antibacterial activity of the best niosomal formulation and free forms was measured against S. aureus in vitro.
Results: The optimal niosomal formulation was obtained by mixing the surfactants (span60 and tween60; 2:1 w/w), cholesterol, and dicetylphosphate at a ratio of 47:47:6, respectively. They showed uniform spherical shapes with the size of 565 and 325 nm for lysostaphin and LL-37, respectively. This formulation showed high entrapment efficiency for the peptide, protein, and a slow-release profile over time. Release kinetic was best fitted by Higuchi model indicating a diffusion-based release of the drugs. The lysostaphin/LL-37 niosomal formulation synergistically inhibited growth of S. aureus for up to 72 hours. However, the same amounts of free forms of both anti-microbial agents could not hold the anti-microbial effect and growth was seen in the following 72 hours. Cytotoxicity assay specified that lysostaphin/LL-37 niosomal combination had no deleterious effect on normal fibroblast cells at effective antimicrobial concentrations.
Conclusion: This study indicated that the use of lysostaphin in combination with LL-37, either in niosomal or free forms, synergistically inhibited growth of S. aureus in vitro. In addition, niosomal preparation of antimicrobial agents could provide a long-term protection against bacterial infections.
Keywords: LL-37, lysostaphin, sustained release, synergy, Staphylococcus aureus
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]